Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Clinical trial NCT06512467 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06512467
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-30
- Primary completion
- 2026-07-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.